Paper Alert: CryoEM Structures of α-Synuclein Published
In stark contrast to Aβ and tau fibrils, α-synuclein fibrils are asymmetric, comprising two different protofibrils.
ALL NEWS
205 RESULTS
Sort By:
Low-Dose BACE Inhibitors Might Preserve Synaptic Function
In cell culture, slashing Aβ production by more than half harmed neuronal signaling, but a smaller cut maintained it.
At CTAD, Early Failures and Hints of Success, from Small Trials
A half-dozen lesser-known compounds in trials for Alzheimer’s disease posted results at the CTAD conference.
Molecular Transport Vehicle Shuttles Therapies into Brain
Built to cross the blood-brain barrier, the vehicle delivers therapeutic antibodies, enzymes, and potentially small molecules such as oligonucleotides.
Disadvantaged Neighborhoods Raise Odds of Alzheimer’s
People who lived in impoverished neighborhoods in their last year of life had greater odds of having died with AD neuropathology.
Social Distancing Shutters Alzheimer’s Research
With experiments and careers on hold, scientists working from home are turning to virtual lab meetings and journal clubs to keep up morale.
Janus-Faced PLCγ2? Alzheimer’s Risk Protein Toggles TREM2 and TLR Pathways
Acting downstream of TREM2, PLCγ2 facilitates phagocytic microglial behavior such as lipid processing. PLCγ2 also acts downstream of toll-like receptors, where it can throw a switch to inflammation.
Does Common Structure Explain Cross-Seeding of Fibrils?
Islet amyloid protein and Aβ fibrils share similar folds.
GnomAD: Stunning Variation Seen in Largest Collection of Human Genomes
In seven papers, researchers presented a dazzling set of findings gleaned from 125,748 exomes and 15,708 genomes housed in a new database. Tidbits emerge on tau, LRRK2, and other proteins implicated in neurodegeneration.
Boost or Block TREM2? Either Way, Therapy May Need Careful Timing
New research suggests the R47H variant protects neurons from neurodegeneration, raising questions about staging and direction of future TREM2-based therapy.
Alzheimer’s Research Restarts, Cautiously
As the SARS-Cov-2 infection peak passes in some areas, scientists are resuming lab work and clinical studies, albeit with new safety protocols in place. Regions differ greatly in how fast they can reopen.
In the Wake of COVID-19: Trials Interrupted, Delayed, Cancelled
Many Alzheimer’s trials had minimal dosing interruptions, but recruitment stopped for a time. Others trials fared worse, with some scrapped altogether. One administered study drug in an ambulance.
Human Blood-Brain Barrier Model Blames Pericytes for CAA
When these tiny mural cells carried APOE4, they secreted more ApoE, causing Aβ to deposit in capillary walls. Blocking ApoE production prevented angiopathy.
Paper Alert: Astrocytes Convert to Neurons (of the Dopaminergic Persuasion)
By suppressing a single gene, scientists triggered the transformation of astrocytes into neurons in the mouse substantia nigra, where the converts released dopamine and connected with the striatum.
Paper Alert: Two ApoE2s Provide “Exceptional” Protection Against AD
Compared with people who carry two copies of ApoE3 or ApoE4, ApoE2 homozygotes had an 87 and 99.6 percent lower risk for AD, respectively.
Current Filters
- Date Range : Oct 2019 to Oct 2020 x